68Ga-PSMA-11 PET/CT对多种临床场景下前列腺癌患者分期与治疗决策的影响:一项前瞻性单中心研究
这项前瞻性单中心研究纳入197例非生化复发、非手术候选的前列腺癌患者,评估68Ga-PSMA-11 PET/CT对分期与治疗决策的影响。PET/CT改变了135/197(69%)患者的分期,并影响了104/182(57%)患者的治疗决策。在放疗后未达Phoenix标准、其他局部治疗后及已知晚期转移等场景中均有显著影响。
要点
- 68Ga-PSMA-11 PET/CT使135/197(69%)患者分期改变,其中38%升期、30%降期。
- 在182例可评估患者中,104例(57%)的治疗决策因PET/CT而改变。
- 放疗后未达Phoenix标准者治疗影响13/18(72%),其他局部治疗后8/12(67%),晚期转移者59/96(61%)。
核心结论
- 在经典两大适应证(生化复发与术前分期)之外的所有受查临床场景中,68Ga-PSMA-11 PET/CT对前列腺癌患者的分期与治疗决策均有深远影响。
研究设计与样本
- 前瞻性单中心研究,纳入197例因非生化复发、非手术候选适应证而行68Ga-PSMA-11 PET/CT的前列腺癌患者。
- 适应证包括非手术候选者的初始分期30例,以及根治性治疗后再分期167例。
- 再分期队列包括已知晚期转移性疾病103例、仅雄激素剥夺治疗后16例、手术后血清前列腺特异性抗原低于0.2 ng/mL者13例、放疗后未达Phoenix标准者22例、其他原发局部治疗(高强度聚焦超声、局灶激光消融、冷冻消融、热疗或不可逆电穿孔)后13例。
- 排除生化复发患者与根治性手术候选者。
- 通过转诊医生填写的PET前后问卷、电子病历审查或患者电话随访评估对治疗决策的影响。
主要发现
- 68Ga-PSMA-11 PET/CT使135/197(69%)患者的分期发生改变,其中升期占38%、降期占30%、分期不变占32%。
- 在182例可评估患者中,104例(57%)的治疗决策受到影响。
- 放疗后未达Phoenix标准者中治疗受影响13/18(72%)。
- 其他根治性局部治疗后患者中治疗受影响8/12(67%)。
- 已知晚期转移性疾病患者中治疗受影响59/96(61%)。
临床怎么用
- 原文结论认为,在经典两大适应证(生化复发与术前分期)之外的所有受查临床场景中,68Ga-PSMA-11 PET/CT对前列腺癌患者的分期与治疗决策均有深远影响。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The impact of prostate-specific membrane antigen (PSMA) PET/CT on management of prostate cancer (PCa) patients with biochemical recurrence (BCR) is well established. However, whether and how PSMA PET/CT affects the management of patients undergoing scans for other clinical indications remains unknown. The goal of this study was to determine the impact of 68Ga-PSMA-11 PET/CT on initial and subsequent management decisions in a cohort of PCa patients referred for various indications (i.e., a basket trial) excluding the 2 main classic indications: BCR and presurgical staging. Methods: This was a prospective study of 197 patients that aimed to determine the impact of 68Ga-PSMA-11 PET/CT on PCa stage and management. The indications for PSMA PET/CT were initial staging of nonsurgical candidates (30 patients) and restaging after definitive treatment (167 patients). The restaging cohort comprised patients restaged with known advanced metastatic disease (n = 103), after androgen deprivation therapy only (n = 16), after surgery and with serum prostate-specific antigen levels lower than 0.2 ng/mL (n = 13), after radiation therapy and not meeting the Phoenix criteria (n = 22), and after other primary local treatments (i.e., high-intensity focused ultrasound, focal laser ablation, cryoablation, hyperthermia, or irreversible electroporation) (n = 13). Patients with BCR and candidates for curative surgery were excluded. Impact on management was assessed using pre- and post-PET questionnaires completed by referring physicians, electronic chart review, or patient telephone calls. Results: PSMA PET/CT changed the disease stage in 135 of 197 (69%) patients (upstaging in 38%, downstaging in 30%, and no change in stage in 32%). Management was affected in 104 of 182 (57%) patients. Specifically, PSMA PET/CT impacted the management of patients who were restaged after radiation therapy without meeting the Phoenix criteria for BCR, after other definitive local treatments, and with advanced metastatic disease in 13 of 18 (72%), 8 of 12 (67%), and 59 of 96 (61%), respectively. Conclusion: PSMA PET/CT has a profound impact on stage and management of PCa patients outside the 2 main classic indications (BCR and presurgical staging) across all examined clinical scenarios.
引用
- Sonni I, Eiber M, Fendler WP, et al. Impact of 68Ga-PSMA-11 PET/CT on Staging and Management of Prostate Cancer Patients in Various Clinical Settings: A Prospective Single-Center Study. J Nucl Med. 2020. PMID: 31924715. doi:10.2967/jnumed.119.237602
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。